Sign In
Buy MDGL
$513.43
+0.550 (+0.107%)
At Close: Jun 23, 2026
Madrigal Pharmaceuticals Reports 2021 First Quarter Financial Results and Highlights
06:50am, Thursday, 06'th May 2021
WEST CONSHOHOCKEN, Pa., May 06, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today its first quarter 2021 financial results and highlights.
Madrigal Pharmaceuticals: Leading The NASH Innovation
04:36am, Wednesday, 05'th May 2021
The Phase 2 data has been excellent while the company is most likely to present strong data for its Phase 3 MAESTRO-NAFLD-1 trial in late 2021.
The Promises Behind Terns' Multi-Pronged Pipeline
07:31am, Friday, 26'th Mar 2021
This pharma may be a newcomer to the stock market, but it has several innovative drugs in development for a common condition with no current treatments approved.
Madrigal Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results and Highlights
06:50am, Thursday, 25'th Feb 2021
WEST CONSHOHOCKEN, Pa., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today its fourth quarter and full year 2020 financial results and highlights.
Reddit playing a major role in biotech trading action, says Jefferies top health care analyst
06:11pm, Thursday, 04'th Feb 2021
Jared Holz, Jefferies managing director and healthcare sector specialist, on which biotech stocks could be the next targets. With Melissa Lee and the Fast Money traders, Guy Adami, Tim Seymour, Karen
Gamestopping Biopharma: These Three Stocks May See A Short Squeeze Soon
06:47am, Sunday, 31'st Jan 2021
The GameStop effect will soon come to biopharma, an usually heavily-shorted sector. Here's a list of three of biopharma's more heavily-shorted stocks.
Madrigal Pharma: A Look At The Early MAESTRO Trial Data
08:00am, Friday, 27'th Nov 2020
In November, Madrigal released open label data from the MAESTRO-NAFLD study. This data was positive, and could be used to make predictions about the entire study.
Madrigal Pharmaceuticals Highlights Presentations at The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting November 13, 2020, Including NASH Expert Insights on the Ongoing Open Label Arm of Resmetirom 52-Week Phase 3 MAESTRO-NAFLD-1 Trial
06:50am, Friday, 13'th Nov 2020
CONSHOHOCKEN, Pa., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), announced that Dr. Stephen Harrison, M.D., Medical Director for Pinnacle Clinical Research, San Anton
CONSHOHOCKEN, Pa., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that it completed enrollment in its MAESTRO NAFLD-1 clinical trial of resmetirom in pa
Terns Pharmaceuticals to Present Clinical Data on Improved TERN-101 Tablet Formulation at the Paris NASH Digital Experience
12:00am, Thursday, 22'nd Oct 2020
Terns Pharmaceuticals to Present Clinical Data on Improved TERN-101 Tablet Formulation at the Paris NASH Digital Experience
Regulatory News: POXEL (Euronext – POXEL - FR0012432516, éligible PEA-PME), société biopharmaceutique spécialisée dans le développement de traitements
89bio: Near And Long-Term Investment Cases Excite As Company Targets NASH Opportunity (NASDAQ:ETNB)
11:01pm, Wednesday, 14'th Oct 2020
89bio has emerged as a competitive player in the race to have a treatment approved for nonalcoholic steatohepatitis (“NASH”) - a potential multi-billion dollar market.
Terns Pharmaceuticals to Present Positive Data on Single-Agent and Combination NASH Programs at The Liver Meeting® Digital Experience 2020
12:00am, Wednesday, 14'th Oct 2020
Terns Pharmaceuticals to Present Positive Data on Single-Agent and Combination NASH Programs at The Liver Meeting® Digital Experience 2020
Inventiva sa : Inventiva décroche une Breakthrough Therapy dans la NASH, une première depuis 2015
07:23am, Tuesday, 13'th Oct 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 12)
10X Genomics Inc (NASDAQ:...
